Stockscreener 앱 받기
6.95
6.08%
-0.45
시장 영업 전:
7.35
0.40
+5.76%
Neurosense Therapeutics Ltd 주식(NRSN)의 최신 뉴스
NeuroSense to file NDS to Health Canada for PrimeC ALS treatment - scanx.trade
NeuroSense to discuss PrimeC Phase 3 plans in Roth ALS webinar - scanx.trade
NeuroSense H1FY27 Results: Net loss narrows to $3.56M, targets Dec 2026 filing - scanx.trade
NeuroSense Advances PrimeC ALS Program and Cuts Costs in H1 2026 - TipRanks
Without delays, cash won't fund 12 months under NeuroSense's (NASDAQ: NRSN) original development plan. - Stock Titan
NeuroSense Provides Business Update and Progress for the First Half of 2026 - PR Newswire
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq - The Globe and Mail
12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com
NeuroSense (NASDAQ: NRSN) cuts share count to 1.9M in 1-for-20 split - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why Is NeuroSense (NASDAQ:NRSN) in Focus Before Tuesday’s Open? - Kalkine Media
Neurosense Therapeutics Stock Price Forecast. Should You Buy NRSN? - StockInvest.us
Amyotrophic Lateral Sclerosis Pipeline 2026: FDA Approvals, - openPR.com
NeuroSense Therapeutics (NRSN) Slips 1.24% to $0.41, Hovering Near Key Support at $0.39Parabolic SAR - dars.gov.et
NRSN Q2'26 Earnings: EPS estimate is (0.20) USD - TradingView
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS - Morningstar
NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval - TipRanks
NeuroSense redesigns PrimeC ALS plan for faster, cheaper approval path - scanx.trade
NeuroSense Therapeutics Ltd. Warrant (NRSNW) Key Financial Ratios – Valuation, Profitability & More - Value Research
NeuroSense (NRSN) gains 12‑month mandate for reverse share split - Stock Titan
NeuroSense Therapeutics Ltd. Warrant (NRSNW) Peer Comparison – Compare with Others - Value Research
NeuroSense Therapeutics Ltd. Revenue Breakdown – NASDAQ:NRSN - TradingView
12 Health Care Stocks Moving In Tuesday's After-Market SessionAlector (NASDAQ:ALEC), NeuroSense Therap - Benzinga
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session - vinanet.vn
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session: Support at $0.36 and Resistance at $0.40 Frame the Range for the Current SessionThrowback Trade - siam.in
NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts - The Globe and Mail
Amyotrophic Lateral Sclerosis Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight - openPR.com
NeuroSense Issues CEO Letter to Shareholders - Nasdaq
NeuroSense Therapeutics (NRSN) Slips to $0.47 as Bulls Defend Key Support FloorNHNL Ratio - dars.gov.et
Global Neurodegenerative Disease Market is Expected to - GlobeNewswire
NRSN Q2 2025 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Pipeline Advances - dars.gov.et
NeuroSense Advances PrimeC Toward December 2026 Health Canada Filing After Completing Pre-NDS Process - TipRanks
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - GuruFocus
Health Canada review path for PrimeC: NeuroSense (NASDAQ: NRSN) - Stock Titan
NeuroSense Therapeutics (NRSN) Jumps 11.35% to $0.52, Nears Key Resistance at $0.55Chart Pattern Alerts - dars.gov.et
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
NeuroSense Therapeutics Ltd. SEC Filing (Aug 3, 2026) - Stock Titan
NRSN Q2 2025 Earnings: Narrower-than-Expected Loss Highlights Clinical-Stage DisciplineShare Dilution Risk - dars.gov.et
NeuroSense Therapeutics Calls August 26 Shareholder Vote on Wide-Range Reverse Share Split - TipRanks
NeuroSense Therapeutics (NRSN) seeks reverse split amid Nasdaq compliance push - Stock Titan
NeuroSense Updates Capital on Demand Program After New F-3 Becomes Effective - TipRanks
NeuroSense Therapeutics (NRSN) sets $150M shelf and $3.8M ATM share plan - Stock Titan
NeuroSense Therapeutics (NRSN) Plunges 14% – Testing Critical Support at $0.46Sentiment Shift - vinanet.vn
Neurosense Therapeutics is a buy, this analyst says - Cantech Letter
Neurosense Therapeutics Ltd expected to post breakeven results a shareEarnings Preview - TradingView
Neurosense Therapeutics Ltd. Revenue Breakdown – FWB:H1Z - TradingView
Neurosense Therapeutics Ltd - TradingKey
Neurosense Therapeutics Ltd (NRSN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurosense Therapeutics Ltd (NRSN) Cash Flow - TradingKey
NRSN|Neurosense Therapeutics Ltd|Price:0.602|Chg%:-0.048 - TradingKey
Neurosense Therapeutics Ltd (NRSN) Valuation: PE, PB & Fair Value Analysis - TradingKey
NRSN|Neurosense Therapeutics Ltd|Price:0.511|Chg%:+0.109 - TradingKey
TradingKey - TradingKey
NeuroSense Therapeutics (NRSN) Gains 3.08% as Stock Tests Key Resistance at $0.70Bollinger Expansion - dars.gov.et
NeuroSense Moves PrimeC Toward Health Canada Drug Submission for ALS - TipRanks
NeuroSense Therapeutics (NASDAQ: NRSN) eyes Canada NDS for ALS drug - Stock Titan
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS - PR Newswire
NRSN Q2 2025 Earnings: Narrower-than-Expected Loss Fails to Soothe ShareholdersNew Analyst Coverage - careplusvn.com
NeuroSense Therapeutics (NRSN) Faces Headwinds: Stock Retreats 5.6% to $0.69 Amid Sector PressureNAAIM Leverage - dars.gov.et
NeuroSense Therapeutics (NRSN) Slips 2.6% as Stock Tests Key Support at $0.65NAAIM Leverage - dars.gov.et
NeuroSense Therapeutics (NRSN) Slides 2.3% as Sellers Test Key Support at $0.66Calendar Spread Trade - dars.gov.et
NeuroSense Therapeutics (NRSN) Edges Higher as Key Support HoldsEquity Put Call - dars.gov.et
NeuroSense Therapeutics Ltd. (NRSN) Latest Stock News & Headlines - Yahoo Finance
3.06%
2.55%
자본화:
|
볼륨(24시간):